Article
Immunology
Chang-Qing Zheng, Hong-Xia Fan, Xiao-Xian Li, Jing-Jie Li, Shuo Sheng, Feng Zhang
Summary: Resveratrol (RES) has shown potential in alleviating dyskinesia associated with Parkinson's disease treatment, reducing the abnormal movements induced by L-DOPA while protecting DA neurons from long-term damage, and inhibiting neuroinflammatory reactions mediated by glial cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Andrea Lopez-Lopez, Rita Valenzuela, Ana Isabel Rodriguez-Perez, Maria J. Guerra, Jose Luis Labandeira-Garcia, Ana Munoz
Summary: Statins have been proposed for the treatment of L-DOPA-induced dyskinesia (LID), and their anti-dyskinetic effects may be related to the inhibition of the Ras-ERK pathway. The mechanisms responsible for the anti-LID effect are unclear, but they could involve changes in cholesterol homeostasis and oxidative stress- and inflammation-related mechanisms. Angiotensin II, cholesterol, and Rho-kinase pathways have been found to interact in LID, and their inhibition by specific drugs may attenuate the dyskinetic symptoms.
Review
Neurosciences
Kai Yang, Xinyue Zhao, Changcai Wang, Cheng Zeng, Yan Luo, Taolei Sun
Summary: LID is a common issue in the treatment of Parkinson's disease, involving damage to multiple brain regions, with various theoretical models proposed to explain its mechanisms, necessitating a deeper understanding.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Pharmacology & Pharmacy
Mariza Bortolanza, Glauce C. do Nascimento, Rita Raisman-Vozari, Elaine Del-Bel
Summary: The study demonstrates that doxycycline and its analogue compound COL-3 have the potential to reduce l-DOPA-induced dyskinesia in hemiparkinsonian rats. Doxycycline can also suppress the onset of dyskinesia when administered together with l-DOPA, while reducing immunoreactivity and activity of certain proteins in the basal ganglia.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Peggy Rentsch, Timothy Egan, Andrea Kuriakose, Sandy Stayte, Bryce Vissel
Summary: L-Dopa treatment for Parkinson's disease can cause dyskinesias, and this study suggests that the increased ratio of M1 to M2 microglia in the striatum is a contributing cause of dyskinesias. Anti-inflammatory drugs can alleviate dyskinesias and reduce the M1/M2 microglia ratio.
JOURNAL OF NEUROCHEMISTRY
(2023)
Article
Geriatrics & Gerontology
Hiromi Sano, Atsushi Nambu
Summary: ZNS is an anticonvulsant drug that has beneficial effects on Parkinson's disease and its side effect, L-DOPA-induced dyskinesia, but can also have adverse effects.
FRONTIERS IN AGING NEUROSCIENCE
(2023)
Article
Cell Biology
Osama F. Elabi, Elena Espa, Katrine Skovgard, Silvia Fanni, Maria Angela Cenci
Summary: Dopamine replacement therapy for Parkinson's disease can use L-DOPA or dopamine D2/3 agonists, such as ropinirole. This study compares the effects of L-DOPA and ropinirole on glial and microvascular reactivity in the striatum. The results show that ropinirole co-treatment with L-DOPA has similar therapeutic effects but prevents maladaptive gliovascular changes associated with L-DOPA treatment.
Article
Neurosciences
Gunasingh J. Masilamoni, Christopher G. Sinon, Brik A. Kochoian, Arun Singh, Andrew J. McRiner, Liza Leventhal, Stella M. Papa
Summary: This study assessed the effects of a selective PDE9 inhibitor (PDE9i) in a primate model of Parkinson's disease (PD). The results showed that PDE9i enhanced the antiparkinsonian effects of L-DOPA and prolonged its duration of action. This suggests that striatal PDE9 inhibition may be a strategy to improve motor responses to L-DOPA in PD.
Article
Neurosciences
Zhihua Liu, Aijuan Yan, Jiahao Zhao, Shuyuan Yang, Lu Song, Zhenguo Liu
Summary: The study revealed the important role of p75NTR in patients with Parkinson's disease and suggested it as a new target for managing L-dopa-induced dyskinesia.
EXPERIMENTAL NEUROLOGY
(2021)
Article
Neurosciences
Sara Corsi, Simona Scheggi, Alessandra Pardu, Giulia Braccagni, Donatella Caruso, Lucia Cioffi, Silvia Diviccaro, Mauro Gentile, Silvia Fanni, Roberto Stancampiano, Carla Gambarana, Roberto Cosimo Melcangi, Roberto Frau, Manolo Carta
Summary: Research suggests a link between imbalances in the neurosteroid pathway and Parkinson's Disease (PD) and L-DOPA-induced dyskinesias (LIDs). Specifically, the neurosteroid pregnenolone has been shown to counter LIDs and has similar effects to the 5 alpha-reductase inhibitor dutasteride. This study highlights pregnenolone as a potential novel tool for targeting LIDs in PD.
EXPERIMENTAL NEUROLOGY
(2023)
Article
Cell Biology
Marc Morissette, Melanie Bourque, Marie-Eve Tremblay, Therese Di Paolo
Summary: Inflammatory markers were found in the brains of Parkinson's disease patients. The study showed that MPEP reduced the development of L-Dopa-induced dyskinesias (LID) in MPTP-lesioned monkeys and decreased inflammatory markers in the brain. The results demonstrated increased inflammatory markers in the basal ganglia associated with LID and revealed the potential of MPEP in reducing LID and inflammatory response.
Article
Neurosciences
Changqing Zheng, Feng Zhang
Summary: Parkinson's disease is a progressive neurodegenerative disorder characterized by motor symptoms, with L-DOPA being the most effective pharmacotherapy. However, L-DOPA can lead to motor fluctuations, including worsening symptoms and dyskinesia. Therefore, investigating the pathogenesis of LID and developing new interventions for its treatment are crucial in the management of PD.
Article
Neurosciences
Keita Sugiyama, Mahomi Kuroiwa, Takahide Shuto, Yoshinori N. Ohnishi, Yukie Kawahara, Yuta Miyamoto, Takaichi Fukuda, Akinori Nishi
Summary: The striatum, the main structure of the basal ganglia, is subdivided into seven subregions with distinct roles in motor and emotional functions. Dopamine D1 receptor signaling is region-specifically regulated in the striatum, with aberrant activation in the IC associated with L-DOPA-induced dyskinesia. Future research focusing on D1 receptor signaling in the IC may lead to novel therapeutics for LID.
JOURNAL OF NEUROSCIENCE
(2021)
Article
Biochemistry & Molecular Biology
Tung-Tai Kuo, Yuan-Hao Chen, Vicki Wang, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Nigel H. H. Greig, Jin Jung, Ho- Choi, Lars Olson, Barry J. J. Hoffer, Kuan-Yin Tseng
Summary: This study evaluated the efficacy of PT320 on L-DOPA-induced dyskinetic behaviors and neurochemistry in a progressive Parkinson's disease MitoPark mouse model. The results showed that early administration of PT320 significantly reduced the severity of L-DOPA-induced abnormal involuntary movements, particularly in excessive standing and abnormal paw movements. However, late administration of PT320 did not improve any L-DOPA-induced dyskinesia measurements. Furthermore, early treatment with PT320 increased both tonic and phasic release of dopamine in striatal slices, indicating its potential role in alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Wen-Shin Song, Tai-Ho Hung, Shing-Hwa Liu, Yin-Ting Zheng, Hsin-Mei Lin, Feng-Yi Yang
Summary: Systemic inflammation is linked to intestinal inflammation and neuroinflammation through the gut-brain axis. Low-intensity pulsed ultrasound (LIPUS) has neuroprotective and anti-inflammatory effects. This study demonstrates that abdominal LIPUS stimulation attenuates LPS-induced colonic inflammation and neuroinflammation, offering new insights into the treatment of neuroinflammation-related brain disorders.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)